Zacks Research Weighs in on Glaukos’ Q4 Earnings (NYSE:GKOS)

Glaukos Co. (NYSE:GKOS) – Zacks Research upped their Q4 2026 EPS estimates for Glaukos in a report issued on Wednesday, May 21st. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings of $0.11 per share for the quarter, up from their previous forecast of $0.06. The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same period in the previous year, the firm earned ($0.70) earnings per share. The firm’s revenue for the quarter was up 24.6% on a year-over-year basis.

GKOS has been the topic of several other reports. Stifel Nicolaus decreased their target price on shares of Glaukos from $140.00 to $115.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Morgan Stanley decreased their target price on shares of Glaukos from $110.00 to $72.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 6th. Stephens reduced their price objective on shares of Glaukos from $140.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. Needham & Company LLC reduced their price objective on shares of Glaukos from $176.00 to $115.00 and set a “buy” rating on the stock in a research report on Thursday, May 1st. Finally, Truist Financial reissued a “buy” rating and set a $135.00 price objective (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.67.

Glaukos Stock Up 2.7%

Shares of NYSE GKOS opened at $97.38 on Thursday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos has a 52 week low of $77.10 and a 52 week high of $163.71. The firm’s fifty day moving average is $93.51 and its 200 day moving average is $124.97. The company has a market cap of $5.56 billion, a price-to-earnings ratio of -33.93 and a beta of 0.83.

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. This trade represents a 2.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Bessemer Group Inc. increased its stake in shares of Glaukos by 133.9% in the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 158 shares in the last quarter. Whipplewood Advisors LLC increased its stake in shares of Glaukos by 3,957.1% in the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 277 shares in the last quarter. First Horizon Advisors Inc. increased its stake in shares of Glaukos by 72.9% in the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 159 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of Glaukos by 583.9% in the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 327 shares in the last quarter. Finally, IFP Advisors Inc bought a new position in shares of Glaukos in the 4th quarter worth about $43,000. 99.04% of the stock is currently owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.